Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer

BACKGROUND. Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)‐positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose‐dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzum...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Yu, Anthony F., Singh, Jasmeet C., Wang, Rui, Liu, Jennifer E., Eaton, Anne, Oeffinger, Kevin C., Steingart, Richard M., Hudis, Clifford A., Dang, Chau T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Breast Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469581/
https://ncbi.nlm.nih.gov/pubmed/28341761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0406
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi